Biochemical Characterization and Validation of a Catalytic Site of a Highly Thermostable Ts2631 Endolysin from the Thermus scotoductus Phage vB_Tsc2631

PLoS One. 2015 Sep 16;10(9):e0137374. doi: 10.1371/journal.pone.0137374. eCollection 2015.

Abstract

Phage vB_Tsc2631 infects the extremophilic bacterium Thermus scotoductus MAT2631 and uses the Ts2631 endolysin for the release of its progeny. The Ts2631 endolysin is the first endolysin from thermophilic bacteriophage with an experimentally validated catalytic site. In silico analysis and computational modelling of the Ts2631 endolysin structure revealed a conserved Zn2+ binding site (His30, Tyr58, His131 and Cys139) similar to Zn2+ binding site of eukaryotic peptidoglycan recognition proteins (PGRPs). We have shown that the Ts2631 endolysin lytic activity is dependent on divalent metal ions (Zn2+ and Ca2+). The Ts2631 endolysin substitution variants H30N, Y58F, H131N and C139S dramatically lost their antimicrobial activity, providing evidence for the role of the aforementioned residues in the lytic activity of the enzyme. The enzyme has proven to be not only thermoresistant, retaining 64.8% of its initial activity after 2 h at 95°C, but also highly thermodynamically stable (Tm = 99.82°C, ΔHcal = 4.58 × 10(4) cal mol(-1)). Substitutions of histidine residues (H30N and H131N) and a cysteine residue (C139S) resulted in variants aggregating at temperatures ≥75°C, indicating a significant role of these residues in enzyme thermostability. The substrate spectrum of the Ts2631 endolysin included extremophiles of the genus Thermus but also Gram-negative mesophiles, such as Escherichia coli, Salmonella panama, Pseudomonas fluorescens and Serratia marcescens. The broad substrate spectrum and high thermostability of this endolysin makes it a good candidate for use as an antimicrobial agent to combat Gram-negative pathogens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Bacteriophages / enzymology*
  • Bacteriophages / physiology
  • Catalytic Domain*
  • Cations, Divalent / pharmacology
  • Endopeptidases / chemistry*
  • Endopeptidases / metabolism*
  • Enzyme Stability
  • Models, Molecular
  • Molecular Sequence Data
  • Sodium Chloride / pharmacology
  • Substrate Specificity
  • Temperature
  • Thermus / virology*

Substances

  • Cations, Divalent
  • Sodium Chloride
  • Endopeptidases
  • endolysin

Grants and funding

The work described in the manuscript was supported by funding from the European Union’s Seventh Framework Programme managed by REA, Research Executive Agency ([FP7/2007-2013] [FP7/2007-2011]) under grant agreement no 286556 to the EXGENOME project (Exgenome Molecular Enzymes). Audur Thorisdottir is employed by VESO Vikan, Namsos, Norway. Sigridur Hjörleifsdottir is employed by ORF Genetics, Kopavogur, Iceland. Jakob K. Kristjansson is employed by Prokazyme ehf, Reykjavik, Iceland. Slawomir Dabrowski is employed by A&A Biotechnology, Gdynia, Poland. VESO Vikan, ORF Genetics, Prokazyme ehf and A&A Biotechnology provided support in the form of salaries for authors AT, SH, JKK and SD respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.